Aileron Therapeutics is a biopharmaceutical company based in Cambridge, MA, that focuses on developing innovative therapies for orphan pulmonary and fibrosis conditions. Through its recent acquisition of Lung Therapeutics and a private investment of $18 million, Aileron is poised to advance its pipeline of first-in-class medicines to address significant unmet medical needs in these diseases.
The company's lead clinical programs include LTI-03, a pioneering compound for idiopathic pulmonary fibrosis (IPF), and LTI-01, a first-in-class treatment for loculated pleural effusion (LPE). With a management team led by CEO Manuel C. Aivado, M.D., Ph.D, and Interim CFO Susan L. Drexler, MBA, CPA, Aileron Therapeutics is committed to providing better treatment options for patients with life-threatening pulmonary conditions.
Generated from the website